Table 1.
Baseline characteristics of studied groups
| Stroke patients D1 N = 52 | Disease controls N = 34 | p value | |
|---|---|---|---|
| Age, years | 69 (± 12) | 68 (± 13) | 0.66 |
| BMI (kg/m2) | 25.4 (23.6–28.4) | 27.0 (25.1–31.1) | 0.37 |
| Females, n (%) | 25 (48) | 13 (38) | 0.39 |
| Hypertension, n (%) | 42 (81) | 30 (88) | 0.56 |
| Diabetes, n (%) | 10 (19) | 6 (18) | > 0.99 |
| Ischemic heart disease, n (%) | 19 (37) | 14 (41) | 0.82 |
| Atrial fibrillation, n (%) | 20 (39) | 3 (9) | < 0.01 |
| Hyperlipidemia (%) | 16 (31) | 12 (35) | 0.81 |
| Smoking, n (%) | 18 (35) | 7 (21) | 0.23 |
| Treatment, n (%) | |||
| Thrombolysis | 16 (31) | – | |
| Antiplatelet drugs | 45 (87) | 34 (100) | 0.72 |
| Anticoagulant | 7 (14) | 0 | 0.04 |
| ACEI | 20 (39) | 17 (50) | 0.37 |
| Diuretics | 23 (44) | 12 (35) | 0.51 |
| CCB | 22 (42) | 17 (50) | 0.51 |
| β-blockers | 9 (17) | 8 (24) | 0.58 |
| ARB | 7 (14) | 1 (3) | 0.14 |
| Statins | 14 (27) | 15 (44) | 0.11 |
| Hypoglycemics | 8 (15) | 4 (13) | 0.78 |
| Insulin | 3 (6) | 3 (9) | 0.68 |
| Stroke etiology (TOAST classification), n (%) | |||
| LVD | 13 (25) | – | – |
| SVD | 12 (23) | – | – |
| CE | 22 (42) | – | – |
| OE | 5 (10) | – | – |
| UE | 0 | – | – |
| Stroke location, n (%) | |||
| TACI | 6 (12) | – | – |
| PAC | 22 (42) | – | – |
| POCI | 13 (27) | – | – |
| LACI | 10 (8) | – | – |
| Stroke lesion volume, mL | |||
| Day 1 | 2.1 (0.3–11.2) | – | – |
| Day 90 | 1.0 (0.4–4.7) | – | – |
ACEI angiotensin convertase enzyme inhibitors, CCB calcium channel blockers, ARB angiotensin receptor blockers, LVD large vessel disease, SVD small vessel disease, CE cardioembolic stroke, OE stroke of other etiology, UE stroke of unknown etiology, TACI total anterior circulation infarcts, PACI partial anterior circulation infarcts, POCI posterior circulation infarcts, LACI lacunar infarcts